These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 20664627)

  • 1. Diabetic nephropathy: Endothelin antagonism for diabetic nephropathy.
    Sarafidis PA; Lasaridis AN
    Nat Rev Nephrol; 2010 Aug; 6(8):447-9. PubMed ID: 20664627
    [No Abstract]   [Full Text] [Related]  

  • 2. Endothelin receptor blockade in patients with diabetic nephropathy.
    Rabelink TJ; Kohan DE
    Contrib Nephrol; 2011; 172():235-242. PubMed ID: 21894003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelin antagonists for diabetic and non-diabetic chronic kidney disease.
    Kohan DE; Pollock DM
    Br J Clin Pharmacol; 2013 Oct; 76(4):573-9. PubMed ID: 23228194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: A systematic review and meta-analysis of randomized controlled trials.
    Zhou Y; Chi J; Huang Y; Dong B; Lv W; Wang YG
    Diabet Med; 2021 Jan; 38(1):e14411. PubMed ID: 33000477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelin-receptor antagonists for diabetic nephropathy: A meta-analysis.
    Yuan W; Li Y; Wang J; Li J; Gou S; Fu P
    Nephrology (Carlton); 2015 Jul; 20(7):459-66. PubMed ID: 25753148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of endothelin receptor antagonists on the progression of diabetic nephropathy.
    Hocher B; Schwarz A; Reinbacher D; Jacobi J; Lun A; Priem F; Bauer C; Neumayer HH; Raschack M
    Nephron; 2001 Feb; 87(2):161-9. PubMed ID: 11244312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice.
    Watson AM; Li J; Schumacher C; de Gasparo M; Feng B; Thomas MC; Allen TJ; Cooper ME; Jandeleit-Dahm KA
    Diabetologia; 2010 Jan; 53(1):192-203. PubMed ID: 19862499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Avosentan reduces albumin excretion in diabetics with macroalbuminuria.
    Wenzel RR; Littke T; Kuranoff S; Jürgens C; Bruck H; Ritz E; Philipp T; Mitchell A;
    J Am Soc Nephrol; 2009 Mar; 20(3):655-64. PubMed ID: 19144760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelin A receptor antagonists in diabetic kidney disease.
    Georgianos PI; Agarwal R
    Curr Opin Nephrol Hypertens; 2017 Sep; 26(5):338-344. PubMed ID: 28520568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects of the endothelin(A) receptor antagonist LU 135252 and the angiotensin-converting enzyme inhibitor trandolapril on diabetic angiopathy and nephropathy in a chronic type I diabetes mellitus rat model.
    Dhein S; Hochreuther S; Aus Dem Spring C; Bollig K; Hufnagel C; Raschack M
    J Pharmacol Exp Ther; 2000 May; 293(2):351-9. PubMed ID: 10773002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential new therapeutic agents for diabetic kidney disease.
    Turgut F; Bolton WK
    Am J Kidney Dis; 2010 May; 55(5):928-40. PubMed ID: 20138415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histamine H
    Pini A; Grange C; Veglia E; Argenziano M; Cavalli R; Guasti D; Calosi L; Ghè C; Solarino R; Thurmond RL; Camussi G; Chazot PL; Rosa AC
    Pharmacol Res; 2018 Feb; 128():18-28. PubMed ID: 29309903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelin antagonist as add-on treatment for proteinuria in diabetic nephropathy: is there light at the end of the tunnel?
    Ritz E; Wenzel RR
    J Am Soc Nephrol; 2011 Apr; 22(4):593-5. PubMed ID: 21415160
    [No Abstract]   [Full Text] [Related]  

  • 14. Atrasentan: The Difficult Task of Integrating Endothelin A Receptor Antagonists into Current Treatment Paradigm for Diabetic Kidney Disease.
    Ortiz A; Fernandez-Fernandez B
    Clin J Am Soc Nephrol; 2021 Dec; 16(12):1775-1778. PubMed ID: 34853063
    [No Abstract]   [Full Text] [Related]  

  • 15. Endothelin receptor blockade in congestive heart failure.
    Cheng TO
    Circulation; 2001 Oct; 104(18):E96. PubMed ID: 11684644
    [No Abstract]   [Full Text] [Related]  

  • 16. Renal protective effect of YM598, a selective endothelin ET(A) receptor antagonist, against diabetic nephropathy in OLETF rats.
    Sugimoto K; Tsuruoka S; Fujimura A
    Eur J Pharmacol; 2002 Aug; 450(2):183-9. PubMed ID: 12206857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atrasentan for the treatment of diabetic nephropathy.
    Egido J; Rojas-Rivera J; Mas S; Ruiz-Ortega M; Sanz AB; Gonzalez Parra E; Gomez-Guerrero C
    Expert Opin Investig Drugs; 2017 Jun; 26(6):741-750. PubMed ID: 28468519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetic nephropathy in 2014: improved cardiorenal prognosis in diabetic nephropathy.
    Parving HH; Rossing P
    Nat Rev Nephrol; 2015 Feb; 11(2):68-70. PubMed ID: 25488854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelin receptor antagonists for aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update.
    Vergouwen MD; Algra A; Rinkel GJ
    Stroke; 2012 Oct; 43(10):2671-6. PubMed ID: 22871682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diuretic medication and change in fluid retention biomarkers during treatment with the endothelin receptor antagonist atrasentan.
    Smeijer JD; Kohan DE; de Zeeuw D; Heerspink HJL
    Diabetes Obes Metab; 2023 Aug; 25(8):2419-2422. PubMed ID: 37157922
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.